Rituximab as a therapeutic option for patients with advanced melanoma

Cancer Immunology, Immunotherapy

Volumn 67, Issue 6, 2018, Pages 917-924

  Winkler, Julia K ^a   Schiller, Matthias ^b   Bender, Carolin ^a   Enk, Alexander H ^a   Hassel, Jessica C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Anti CD 20 antibody; Immunotherapy; Melanoma; Rituximab

Indexed keywords

RITUXIMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY SURFACE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INFUSION RELATED REACTION; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; RITUXIMAB;

EID: 85042934955     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-018-2145-9     Document Type: Article

References (20)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. 10.3322/caac.21254
2. Grossmann KF, Margolin K (2015) Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 7:181–191. 10.1177/1758834015572284
3. Maurer M, Somasundaram R, Herlyn M, Wagner SN (2012) Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches. Oncoimmunology 1:1454–1456. 10.4161/onci.21357
4. Bittner M, Meltzer P, Chen Y et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536–540. 10.1038/35020115
5. Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337. 10.1158/0008-5472.CAN-05-1343
6. Chiaruttini G, Mele S, Opzoomer J, Crescioli S, Ilieva KM, Lacy KE, Karagiannis SN (2017) B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. Oncoimmunology 6:e1294296. 10.1080/2162402X.2017.1294296
7. Ladanyi A, Kiss J, Mohos A et al (2011) Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60:1729–1738. 10.1007/s00262-011-1071-x
8. Garg K, Maurer M, Griss J, Bruggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, Wagner SN (2016) Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol 54:157–164. 10.1016/j.humpath.2016.03.022
9. Saul L, Ilieva KM, Bax HJ et al (2016) IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep 6:29736. 10.1038/srep29736
10. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27:273–281
11. Schwartz M, Zhang Y, Rosenblatt JD (2016) B cell regulation of the anti-tumor response and role in carcinogenesis. Immunother Cancer 4:40. 10.1186/s40425-016-0145-x
12. Egbuniwe IU, Mohamad MH, Karagiannis SN, Nestle FO, Lacy KE (2012) Interleukin-10-producing B-cell subpopulations in melanoma. British society for investigative dermatology meeting, Exeter. Br J Dermatol 166:e15–e40 (Poster P-21)
13. Somasundaram R, Zhang G, Fukunaga-Kalabis M et al (2017) Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:607. 10.1038/s41467-017-00452-4
14. Schmidt P, Abken H (2011) The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2:313–320. 10.18632/oncotarget.259
15. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H (2011) Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108:2474–2479. 10.1073/pnas.1009069108
16. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15:1109–1114. 10.1093/annonc/mdh280
17. Schlaak M, Schmidt P, Bangard C, Kurschat P, Mauch C, Abken H (2012) Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget 3:22–30. 10.18632/oncotarget.437
18. Pinc A, Somasundaram R, Wagner C et al (2012) Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther 20:1056–1062. 10.1038/mt.2012.27
19. Song H, Su X, Yang K et al (2015) CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells. J Biomed Nanotechnol 11:1927–1946
20. Westin JR, Chu F, Zhang M et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69–77. 10.1016/S1470-2045(13)70551-5